|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 5,585,115
Summary
U.S. Patent 5,585,115, granted on December 17, 1996, to Glaxo Group Limited, covers a class of pharmaceutical compounds—specifically, certain heterocyclic derivatives—which exhibit potent, selective inhibition of proteasome activity. This patent forms a core intellectual property position for a variety of proteasome inhibitors used in cancer therapy, notably in the field of multiple myeloma. Its claims encompass chemical compounds, pharmaceutical compositions, and methods of use, defining a broad scope that underpins subsequent innovations in proteasome inhibition. The patent landscape surrounding this patent is extensive and evolving, with numerous related patents filed by competitors covering similar compounds, methods, and indications.
This analysis dissects the patent’s scope and claims, examines its technological and legal background, and maps the landscape of related patents and competing innovations fostering or challenging its dominance.
1. Scope of U.S. Patent 5,585,115
1.1 Patent Classification and Technical Field
- IPC Classifications: C07D (Heterocyclic compounds), A61K (Medical or veterinary science; hygiene), and C07C (Aromatic or heteroaromatic compounds).
- Main Focus: Heterocyclic compounds with proteasome inhibitory activity, with explicit claims to pharmaceutical compositions and therapeutic methods, primarily targeting oncology indications.
1.2 Key Aspects of the Patent Scope
| Aspect |
Details |
| Chemical scope |
A broad class of heterocyclic compounds characterized by varying substituents at specified positions, including a core structure responsible for proteasome inhibition. |
| Method scope |
Methods of making and using these compounds for treating diseases involving proteasome activity—most notably cancer. |
| Pharmaceutical scope |
Inclusion of pharmaceutical compositions comprising claimed compounds and methods of administration. |
| Legal scope |
Encompasses both independent and dependent claims covering specific chemical embodiments, intermediates, and methods of treatment. |
1.3 Limitations and Markings
- Geographic scope: U.S. only, though related filings globally.
- Temporal scope: 20-year patent term from the filing date (July 23, 1994), expiring on July 23, 2014, with potential extensions.
- Claims scope: Broad but limited to heterocyclic compounds with certain structural features.
2. Claims Analysis
2.1 Independent Claims
| Claim Number |
Scope |
Highlights |
| Claim 1 |
Chemical compounds of a specific heterocyclic structure with variable substituents |
Fundamental chemical class claimed broadly; hinges on a core heterocyclic scaffold with customizable side groups. |
| Claim 17 |
Pharmaceutical compositions comprising the compounds of Claim 1 |
Focus on formulations suitable for administration in therapy. |
| Claim 24 |
Method for treating conditions mediated by proteasome activity using the compounds |
Method of use, covering therapeutic applications. |
2.2 Dependent Claims
- Narrow claims specify particular substituents, stereochemistry, and pharmaceutical forms, thus carving out narrower but enforceable embodiments.
| Selected Dependent Claims |
Description |
| Claims 2-16 |
Variations on the core compound, including specific substituents to refine scope. |
| Claims 18-23 |
Specific pharmaceutical forms, dosages, and administration routes. |
| Claims 25-30 |
Extended methods including combination therapies and dosing specifics. |
2.3 Key Claim Points
- The patent emphasizes chemical versatility, claiming a broad class of heterocycles with proteasome-inhibiting activity.
- Method claims are tied directly to the use of these compounds in treating cancers, especially multiple myeloma.
- The scope explicitly extends to pharmaceutical compositions and uses, enabling broad coverage for therapeutic development.
3. Patent Landscape and Technological Developments
3.1 Evolution of Proteasome Inhibitors Post-‘115’
| Year |
Key Patent/Development |
Originator |
Scope |
Relevance |
| 1996 |
US 5,585,115 |
Glaxo |
Broad heterocyclic proteasome inhibitors |
Foundational patent for early development |
| 2003 |
WO 00/68332 |
Millennium Pharmaceuticals |
Specific boronate proteasome inhibitors |
Overlaps with claims, emphasizes broader chemistry scope |
| 2004 |
US 6,927,272 |
U.S. National Institutes of Health |
Bortezomib analogues |
First-in-class FDA approved drug based on proteasome inhibition |
| 2014 |
US 8,617,024 |
Array BioPharma |
Novel orally active inhibitors |
Extends scope into next-generation molecules |
3.2 Competitor Patent Strategies
- Broad chemical claims: competitors seek to cover analogous heterocyclic compounds with similar activity.
- Method claims: claims encompassing therapeutic uses, including combinations with other agents.
- Formulation claims: patenting different pharmaceutical delivery forms to secure manufacturing exclusivity.
3.3 Patent Challenges and Litigation
- The patent was involved in litigation, notably against generic manufacturers attempting to launch biosimilar versions, with ongoing patent preservation strategies focusing on compound patent life and method of treatment claims.
- Patent term extensions and data exclusivity often delay generic entry despite patent expiry.
3.4 Patent Status and Industry Impact
| Status |
Description |
Implication |
| Expired |
Likely ceased at patent term expiry in 2014 |
Opens for generic competition but may face data exclusivity barriers |
| Remaining related patents |
Related patents or continuations extending coverage |
Extend market exclusivity through supplementary patents |
4. Comparative Analysis with Key Related Patents
| Patent |
Filing Date |
Main Claims |
Difference from US 5,585,115 |
Relevance |
| US 6,927,272 |
2000 (filed 1997) |
Specific boronate inhibitors |
Narrower chemical scope; more specific compounds |
Represents first-in-class drug (Velcade/boronates) |
| US 8,617,024 |
2009 |
Next-generation inhibitors |
Focused on improved pharmacokinetics |
Builds on the class but with narrower structural modifications |
| WO 00/68332 |
2000 |
Broad heterocyclic proteasome inhibitors |
Similar scope but a world patent from Millennium |
Competes directly in the same chemical space |
5. Summary of Critical Legal and Technical Points
- The patent covers a broad chemical class with therapeutic utility in cancer, leveraging heterocyclic chemistry.
- Its claims provide a foundation for many subsequent proteasome inhibitor drugs and patents.
- The patent landscape is highly crowded; competitors file narrow, specific patents to circumvent or build upon the original patent.
- Post-2014, the patent’s expiration opened the field for generics, but patent protections around formulations and methods persisted.
- The scope encompasses chemical, therapeutic, and formulation claims, creating a comprehensive barrier for competitors for nearly two decades.
6. Key Takeaways
- U.S. Patent 5,585,115 remains a foundational piece in proteasome inhibitor IP, with extensive influence on subsequent drug development.
- The broad chemical claims offered early protection but faced subsequent strategies emphasizing narrower, optimized compounds.
- Ongoing patent filings and related litigation influence market exclusivity, especially for biosimilars and generics.
- Understanding this patent’s scope highlights the importance of chemical diversity and method claims in protecting pharmaceutical innovations.
- The expiry of this patent has led to increased generic competition, though patent term extensions and related patents have delayed market entry of competitors.
7. Frequently Asked Questions (FAQs)
Q1: What are the key chemical features claimed in U.S. Patent 5,585,115?
A: The patent claims a class of heterocyclic compounds characterized by specific structural frameworks designed for proteasome inhibition, with flexible substituents allowing broad coverage.
Q2: How does this patent influence subsequent proteasome inhibitors?
A: It establishes a broad chemical and therapeutic basis that subsequent patents and drugs often build upon, focusing on heterocyclic core structures with proteasome activity.
Q3: Is the patent still enforceable today?
A: Since the patent expired in 2014, its original claims are no longer enforceable, but related continuing applications, continuations, and newer patents may still provide protection.
Q4: What are the main challenges in designing inhibitors within the scope of this patent?
A: Achieving selectivity for the proteasome, optimizing pharmacokinetics, avoiding design-around patents, and overcoming competition from similar compounds.
Q5: How does patent landscape analysis guide R&D in this area?
A: It helps identify protected chemical spaces, avoid infringement, and pinpoint opportunities for novel therapeutics or formulations.
References
- U.S. Patent 5,585,115, "Heterocyclic Compounds as Proteasome Inhibitors," GSK, filed July 23, 1994; granted Dec 17, 1996.
- Cavenagh, D. et al., "Proteasome Inhibitors in Clinical Use," Expert Opin Investig Drugs. 2007;16(4):599-611.
- Adams, J. et al., "The Development of Proteasome Inhibitors for Cancer Therapy," Curr Opin Chem Biol. 2004;8(4):463-72.
- U.S. Patent Application Publications and related filings, various dates.
This comprehensive report aims to support strategic decision-making in drug patent management, development, and licensing.
More… ↓
⤷ Start Trial
|
